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Abstract HIV infection inWestern Europe is mainly concen-
trated among men who have sex with men, heterosexuals who
acquired HIV from sub-Saharan African countries, and in
people who inject drugs. The rate of newly diagnosed cases
of HIV has remained roughly stable since 2004 whereas the
number of people living with HIV has slowly increased due to
new infections and the success of antiretroviral therapy in
prolonging life. An ageing population is gradually emerging
that will require additional care. There are large differences
across countries in HIV testing rates, proportions of people
who present to care with low CD4+ cell counts, accessibility
to treatment and care, and rates of retention once in care.
Improved collection of HIV surveillance data will benefit
countries and help to understand their epidemic better. How-
ever, social inequalities experienced by people with HIV still
remain in some regions and urgently need to be addressed.
Keywords HIVinfection . HIV/AIDS . HIV .Western
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Introduction
HIV infection has had a large impact in Western European
countries over the last 35 years of the pandemic and continues
to affect growing numbers of people. In this review, we
summarise key issues and highlight recent articles surround-
ing the evolution of the HIVepidemic in Western Europe. We
focus on the 23 countries found in the West region of the
World Health Organisation (WHO) European region
(Table 1).
Current State of the Epidemic
The Joint United Nations Programme on HIV/AIDS
(UNAIDS) estimates that 860,000 [800,000–930,000] adults
were living with HIV in this area of Europe by the end of 2012
[1]. This figure is estimated to have been 360,000 [320,000–
400,000] and 570,000 [520,000–600,000] in 1990 and 2000
respectively [1]. UNAIDS estimates are calculated using the
Spectrum/Estimation and Projection Package (EPP) software
and require country-specific HIV surveillance and survey data
[2, 3]. The increasing trend in number of people living with
HIV in Europe is a combined result of continued new infec-
tions and people living longer because of the success of
antiretroviral therapy (ART) [4].Mortality rates in people with
HIV have declined substantially, with most countries in West-
ern Europe having observed at least a 50 % decline from the
peak in the mid-1990s to present [5••]. Disability-adjusted life
years (DALYs) are used to measure the overall burden of a
disease and can be interpreted as the years of potential life lost,
due to premature death, disability or ill-health. DALYs are
calculated by summing the years of life lost due to premature
mortality and the years lived with disability. Estimates of
DALYs for HIV in Western Europe are significantly lower
than any other region in the world, in which no country has
greater than 60,000 DALYs attributed to HIV (Table 1). This
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compares with 11,915,000 DALYs in South Africa where
HIV is the leading cause of DALYs, and 588,000 DALYs in
the United States [5••].
In 2012, there were 27,315 newly diagnosed cases of HIV
reported in Western Europe [6]. This translates to a rate of 6.6
newly diagnosed cases of HIV reported per 100,000 popula-
tion. The rates of newly diagnosed cases have remained stable
since 2004 (all countries except Monaco have been reporting
data since 2004 to the European Centre for Disease Prevention
and Control, ECDC), with an average of between 6.5 and 7.8
cases per 100,000 each year. Trends over time in this rate
however, differ substantially by mode of HIV transmission
(Fig. 1) among countries where this has been routinely col-
lected since 2004.
Countries in Western Europe largely have concentrated
HIV epidemics, that is, epidemics which are concentrated
among sub-populations, particularly men who have sex with
men (MSM) and people who inject drugs (PWID). The
number of reported HIV diagnoses per year has declined in
most transmission groups, including among PWID, cases of
mother-to-child transmission (MTCT) and heterosexually ac-
quired cases. Worryingly, a slow but steady increase has been
observed in cases amongMSM, largely due to rises in number
of reported cases in the UK, Belgium, Germany and Israel.
The UK contributes around a third of all reported diagnoses
among MSM.
The reported data suggest that the HIVepidemic inWestern
Europe is being fuelled mainly by sexual transmission. In
2012, the distribution of new reported HIV diagnoses by
mode of transmission was as follows: sex between men
41.7 %, heterosexual sex 35.3 %, injecting drug use 5.1 %,
MTCT 0.7 % and unknown 17.2 %. For every one female
diagnosed with HIV, there were 3.1 males diagnosed. Among
reported cases in 2012, 9.8 % were in people aged 15 to
24 years old and 16.7 % of cases in people over the age of
50 [6].
Table 1 Data from 2012 on the
HIVepidemic in Western Europe:
number of HIV diagnoses, esti-
mated number of people living
with HIV and disability-adjusted
life years (DALYs) attributable to
HIV/AIDS
1) A “best” estimate of the num-
ber of people living with HIV in
2012 by country is not given by
UNAIDS. 2) DALYs are calcu-
lated as the summation of YLLs
(years of life lost due to premature
mortality) and YLDs (years lived
with disability). Disability
weights used to calculate YLDs in
reference [5••] were: 0.339 for
HIV disease resulting in myco-
bacterial infection, 0.051 for HIV
pre-AIDS asymptomatic, 0.221
for HIV pre-AIDS symptomatic,
0.053 for AIDS with
antiretrovirals and 0.547 for
AIDS without antiretrovirals
Country Country population as
of 2013 (per million)
[48]
Number of HIV
diagnoses in 2012
[6]
UNAIDS estimate1
of the number of
people living with
HIV in 2012 [1]
Number of DALYs2
attributable to HIV/
AIDS (in thousands)
[5••]
N Rate (per
100,000
population)
Lower
estimate
Upper
estimate
Andorra 0.09 2 2.4 – – 0.0
Austria 8.2 306 3.6 13,000 25,000 3.8
Belgium 10.4 1227 11.1 16,000 26,000 5.3
Denmark 5.6 201 3.6 5500 7500 2.8
Finland 5.3 156 2.9 2600 3600 1.2
France 66.0 4066 6.2 120,000 180,000 48.9
Germany 81.1 2593 3.6 62,000 78,000 29.2
Greece 10.8 1059 9.4 9300 13,000 26.7
Iceland 0.3 219 2.2 <500 <1000 0.4
Ireland 4.8 339 7.4 6300 10,000 1.7
Israel 7.7 487 6.4 6700 11,000 3.2
Italy 61.5 3898 6.4 110,000 140,000 55.3
Luxembourg 0.5 54 10.3 <1000 1100 0.3
Malta 0.4 30 7.2 <500 <500 0.1
Monaco 0.03 0 0 – – –
Netherlands 16.8 976 5.8 20,000 34,000 5.2
Norway 4.7 242 4.9 3600 6300 1.2
Portugal 10.8 721 7.0 38,000 62,000 42.8
San Marino 0.03 5 15.5 – – –
Spain 47.4 3210 8.5 140,000 170,000 56.2
Sweden 9.1 363 3.8 7200 13,000 1.9
Switzerland 8.0 643 8.1 16,000 27,000 6.8
United
Kingdom
63.4 6358 10.3 76,000 120,000 22.2
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Surveillance of the Epidemic
Knowledge and understanding of epidemics, including mon-
itoring of epidemiological trends and patterns is crucial to
inform public health interventions and policies. UNAIDS
and WHO have recently published new comprehensive HIV
surveillance guidelines to reflect the changing situation, nota-
bly wider access to antiretroviral therapy (ART) and preven-
tion of mother-to-child transmission (PMTCT) approaches
[7]. On the European level, surveillance for HIV infection
has been conducted jointly by ECDC and WHO Regional
Office for Europe (WHO/E) since 2007 [8] and by EuroHIV
previously [9]. Countries are requested to report each year, the
number of HIV diagnoses, AIDS diagnoses, CD4 cell + count
(CD4 count) at diagnosis and number of HIV tests performed,
to the ECDC through The European Surveillance System
(TESSy).
Reports on the number of HIVandAIDS diagnoses, known
as ‘case reporting’, form the backbone of HIV surveillance in
Europe. Most countries in Western Europe now have nation-
ally established HIV/AIDS case reporting systems (Italy re-
ported national-level data for the first time in 2012 and Spain
report aggregate regional-level data, for which coverage has
been gradually increasing over time). Many countries also
conduct prevalence surveys and cross-sectional qualitative
surveys on a regular basis to estimate HIV prevalence and
indicators of transmission risk behaviours in key sub-
populations [10, 11]. Second generation surveillance of HIV
includes surveillance of risk behaviour and surveillance of
sexually transmitted infections in addition to case reporting
[7]. HIVantibody assay-based approaches to estimate whether
an infection was acquired recently (4–12 months) are increas-
ingly used to estimate HIVincidence [12, 13•, 14]. In addition,
the SPREAD surveillance programme monitors levels of
transmitted drug resistance in newly diagnosed treatment-
naïve individuals across Europe [15].
Information obtained through surveillance can contribute
to producing estimates of the numbers of people living with
HIV and equally importantly, the numbers of people infected
but not yet diagnosed. Although the quality and quantity of
data collected through surveillance by countries in Western
Europe have improved over time, there still remain tricky
issues over possible under- and delayed-reporting of cases.
One modelling study in 2008 estimated that 35 % of HIV-
positive individuals were thought to be undiagnosed in the
whole ofWestern Europe [16]. As yet, relatively few countries
have carried out any modelling work to estimate the size of the
undiagnosed population in their own countries.
HIV Care Cascade
The first stage of the spectrum of engagement in HIV care,
otherwise commonly referred to as the ‘HIV care cascade’, is
the proportion of people with HIV who are aware of their
diagnosis status [17]. The subsequent stages are: proportion
linked to HIV care, proportion retained in HIV care, propor-
tion receiving ART, and then the proportion with viral sup-
pression. The care cascade is a useful concept to quantify the
success of HIV care services and access to ART. Increasing
the proportion of HIV-positive people who are on ART with
viral suppression is an important aim for HIV prevention, as
those with viral suppression are unlikely to transmit HIV [18,
19]. It is encouraging to see that many countries have started
to provide such figures, with many reporting that approxi-
mately 60 to 70 % of diagnosed HIV-infected individuals are
thought to have an undetectable viral load [20–22].
Testing
A reduction in the proportion of people with HIV who are
undiagnosed will be primarily achieved through expansion in
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Fig. 1 Trends of reported HIV diagnoses by mode of transmission and
year of diagnosis in Western Europe. Data not included from Italy and
Spain as population coverage of HIV surveillance has increased during
this time period. Figure from: European Centre for Disease Prevention
and Control/WHO Regional Office for Europe: HIV/AIDS surveillance
in Europe 2012 [6]
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coverage and frequency of HIV testing. Even in Western
Europe, where ART is widely and generally freely available
to all those diagnosed and in need, HIV testing rates vary
substantially from 1.9 (Greece) to 119.5 (San Marino) tests
performed per 1000 population (where data are collected and
excluding unlinked anonymous testing and testing of blood
donations) [6]. As a large proportion of transmissions are
thought to originate from individuals who are not yet diag-
nosed [23, 24], earlier and more frequent testing is paramount
to benefit, both on an individual- and population-level. In
particular, the HIV in Europe Initiative (www.hiveurope.eu)
has been successful in promoting optimal HIV testing and
earlier care in Europe [25]. Delineation of persons presenting
late for care have identified that many were in contact with the
health system several times before being diagnosed and hence
increased provided-initiated testing is likely to be helpful. The
HIV Indicator Diseases across Europe Study (HIDES) was a
result of the HIV in Europe 2007 Conference, with the aim to
improve targeted testing for people most likely to be infected
with HIV [26]. The study authors found that it would be cost-
effective to offer an HIV test to anyone presenting with one of
eight indicator conditions (sexually transmitted infection,
lymphoma, cervical or anal cancer/dysplasia, herpes zoster,
hepatitis B/C, mononucleosis-like illness, unexplained
leukocytopenia/thrombocytopenia and seborrheic dermatitis/
exanthema) [27•].
Although many European countries already have na-
tional guidelines for HIV testing [28], ECDC has also
issued an evidence-based guidance for tes t ing
programmes to help inform recommendations and scale
up testing further [29]. Access to testing however seems
to vary widely across healthcare settings in Europe:
although most countries offer HIV tests in HIV clinics,
sexual health clinics, hospitals and antenatal settings,
tests are less available through general practitioners,
prisons and tuberculosis services [28]. HIV testing has
also been found to be feasible in emergency departments,
community-based centres and through use of laboratory-
based testing of oral fluid, where each have their own
benefits and difficulties in implementation [30–33, 34•].
A systematic review assessing barriers to testing in Eu-
rope found that there are barriers concerning patients,
healthcare providers and at the level of institutions,
which include perceived low-risk, fear, accessibility, as
well as lack of financial and human resources [35].
These need to be addressed to ensure earlier diagnosis
and wide access to care to prevent excess morbidity and
mortality. Nonetheless, there is momentum to normalise
HIV testing, by means of routine testing such as wider
use of opt-out testing, including use of rapid testing, self-
sampling (where the sample is posted for the test to be
performed), and self-testing (where the person both takes
the sample and performs the test themselves) [36, 37].
Late Presentation
Despite the aforementioned efforts to encourage earlier and
more frequent HIV testing and targeting at-risk populations,
late presentation (presentation with low CD4 count) is unfor-
tunately not a rarity. A consensus definition has been agreed in
order to identify the extent to which it occurs [38, 39]. A
common definition of late presentation is important. The term
“late” indeed is central, as guidelines across the continent
agree that ART should be started before the CD4 count drops
below the threshold of 350 cells/mm3. Conversely, “late”may
not necessarily imply that the person has been infected for
several years, since data from seroconverter cohorts suggest
that for around 20 % of people, the CD4 count is below 350
cells/mm3 by one year from infection [40]. Among adult HIV
diagnoses in the EU/EEA (European Union and European
Economic Area) region reported to ECDC (56 % complete-
ness in 2011), 49 % were reported as late presentations (CD4
count at diagnosis <350 cells/mm3) and 29%were reported as
advanced HIV disease (CD4 count at diagnosis <200 cells/
mm3) [8]. A large cohort collaboration study found that late
presentation in Europe has declined from 57.3 % in 2000 to
51.7 % in 2010/2011; however late presentation was found to
be most prevalent in heterosexual males, Southern European
countries (Greece, Israel, Italy, Portugal and Spain), and peo-
ple originating from Africa, suggesting key populations and
regions for priority interventions [41••].
Access and Retention in Care
Retention in care includes both linkage to care following a
diagnosis and subsequent retention in care. In particular, a
clear and established pathway for onward referral for patients
who test HIV-positive is intrinsic to achieve good rates of
integration into HIV care services for timely ART initiation
and attaining viral suppression. Many of the barriers that limit
access to and retention in care elsewhere have been reduced
and even removed in healthcare systems in Western Europe.
Care is generally free and focuses not only to treat HIV
infection but also co-infections and co-morbidities, including
addiction and psychiatric diseases [42]. There are a minority
of settings of concern that do not provide universal access to
HIV prevention, treatment and care. The recent change in
legislation in Spain preventing illegal immigrants from
accessing HIV care is one notable example [43]. However,
most people on ART in centres across Western Europe expe-
rience continued complete viral control. The level of viral load
is the main predictor of HIV transmission risk [44]. Therefore
the higher the proportion of people with suppressed viral load,
the less chance of transmission of both drug-susceptible and
drug-resistant strains. Perhaps largely due to on-going high
rates of suppression in Europe, prevalence of transmitted drug
resistance has been maintained below 10 % [45].
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As life expectancies have improved over time in people
living with HIV, we are now used to seeing a situation in
Western Europe where a large group of people seen in care are
over the age of 50 [46, 47]. The proportion of newly diag-
nosed cases of HIV in people aged 50 and above has also been
gradually increasing each year, up from 11.9 % in 2006 to
16.6% in 2012 [6]. It will therefore be important to ensure that
HIV care services are adapted so that the needs of older people
living with HIV are met. A more integrated approach to
managing care may be appropriate, which would involve
working closer with primary care physicians to manage
HIV-related conditions but also non-HIV-related conditions
which occur more frequently with older age.
Men Who Have Sex with Men (MSM)
Prevalence and Incidence
HIV infection has had a large impact on MSM in Western
Europe and it still remains the predominant mode of HIV
transmission. Reported prevalence is high, ranging from 0.5
to 17.7 % [49]. The highest prevalences were found in France
(17.7 %), Spain (13.1 %), Greece (12.7 %) and Germany
(11.5 %). It is important to note here that these data were from
various sources, mainly prevalence surveys, conducted in
each country separately and may differ greatly by risk group
definition, definition of a man who has sex with men, repre-
sentativeness of the sample and sample size.
The UK, France, Netherlands, Germany, Denmark and
Spain are examples of countries that have seen a gradual rise
in the number of HIV diagnoses reported among MSM [8].
Studies published in the last few years have indicated that
these rises are not just a result of higher testing rates and better
surveillance systems, but are a result of an increase in trans-
mission by condom-less sex [14, 50–52, 53•]. In many of
these new infections, the probable source is thought to be
HIV-positive people who are not yet diagnosed. These obser-
vations have been seen despite high ART coverage in people
with CD4 count <350 cells/mm3 [54].
Risk Behaviour
Results from the European MSM Internet Survey (EMIS)
found that men known to be HIV-positive were 2.4-fold more
likely to report condom-less sex with a partner of discordant or
unknown status (CLS-D) than HIV-negative and untestedmen
[55]. The proportion of men who had CLS-D with any male
partner in the preceding 12 months ranged from 25 to 41 %.
The study also found that countries in the Central-West and
West regions had the lowest levels of CLS-D whereas coun-
tries in the South-East regions had the highest levels. Similar-
ly, condom-use at last anal intercourse with a male partner also
ranged from 28 to 76% over 35 countries in Europe, although
around half the countries reported proportions between 40 and
60 % [49]. Despite the limitations of the uncertain represen-
tativeness of those sampled, and the potential for social desir-
ability bias in reporting, these data seem to indicate that sexual
risk behaviour amongMSM varies considerably from country
to country.
Heterosexual Transmission
Migration from Countries with Generalised HIV Epidemics
Migrants from countries with generalised HIV epidemics,
mainly from sub-Saharan Africa, represent a large proportion
of heterosexually-acquired HIV and AIDS case reports in
Western Europe. Although there are large disparities due to
former colonial links, healthcare systems and social structures,
the general trend is such that countries with large migrant
populations in the general population will have large numbers
of migrants among those presenting with HIV [56]. The
reported number of cases of HIV diagnoses inWestern Europe
originating from sub-Saharan Africa has nearly halved in the
years between 2006 and 2012 (Fig. 1) [6]. In contrast, for
example in the UK, there has been a rise in the proportion of
diagnoses among people born abroad but who probably ac-
quired their infection in the UK [57].
Of individuals infected through heterosexual contact and
diagnosed in 2011, the proportion of reported cases in people
originating from a country with a generalised epidemic varied
from 5.6 % in Finland to 66.4 % in Ireland, which are much
higher than levels seen in Central and Eastern European
countries [6]. A major concern is that more than 60 % of
migrants from generalised epidemic countries are considered
to be late presenters [58] and many probably have a CD4
count below 350 cells/mm3 before arrival in Europe. As
mentioned earlier, although many countries recognise that
migrants and ethnic minorities are particularly vulnerable to
HIV [59], testing and care are not universally available in all
settings, particularly for those with uncertain or illegal migrant
status.
Migration from East to West
The effect of migration from Eastern to Western Europe is
unclear, but absolute numbers of European migrants diag-
nosed with HIV are small to date [56]. The exceptions are
for countries with close borders to countries in the Eastern
Europe and Central Asia region where the epidemic has
around the turn of the millennium been mainly driven by
injecting drug use, but more recently mixed with heterosexual
and some MSM transmission [60, 61].
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Injecting Drug Use
Importance of Harm-Reduction Services
Across Western Europe, there have been low rates of new
infections among PWID due to the wide implementation and
success of harm-reduction policies and services [6]. Where
data are available, it seems that all countries in Western
Europe provide needle and syringe exchange programmes,
opioid substitution treatment (OST) and ART for PWID,
which is much higher than the average global coverage [62].
However, a number of European countries reported a rise
in the number of new HIV diagnoses among PWID in 2011,
most notably Greece and Romania [63•]. Both countries re-
ported a ten-fold rise; in Greece, the number of HIV diagnoses
increased from 22 cases in 2010 to 245 cases in 2011 and
similarly in Romania, from nine cases in 2010 to 108 cases in
2011 [8]. Greece attributes the outbreak to the shortage of
needle and syringe exchange programmes and long waiting
times for access to OST prior to 2011 [64]. In Romania,
evidence from behavioural surveillance surveys conducted
in PWID suggested changes in drug-use patterns
(amphetamine-type stimulants, associated with more
frequent injections and increased sharing of injecting
equipment, became more common than heroin) [64]. Howev-
er similarly to the situation in Greece, access to harm reduc-
tion services also declined alongside due to the withdrawal of
international programs and funding support [63•, 64]. These
recent outbreaks of HIV transmission among PWID serve as a
reminder that these policies are fragile and vulnerable in
countries affected by economic constraints, and stress the need
for continuing public health and preventative services.
Co-Infection with Hepatitis C
PWID are at the highest risk of being co-infected with hepatitis
C virus (HCV). Of patients in a Europe-wide cohort 78%who
were HCV-positive had acquired HIV-1 via injecting drug use
and most likely acquired HCV through this route too [65]. For
people with HCV, co-infection with HIV is known to be
strongly associated with poorer prognosis with an increased
risk of developing liver disease and HCV-related mortality
[66]. Expanded access to HCV diagnosis and treatment will
therefore be important in conjunction with harm-reduction and
HIV-related programs to control the evolving epidemic.
Mother-to-Child Transmission (MTCT)
The probability of a child with an HIV-positive mother being
born with HIV have now reduced to approximately 1 to 2% in
Western Europe, due to effective preventative interventions
including universal antenatal testing, caesarean sections,
formula feeding and particularly through use of ART [67,
68]. However over the last decade, it has been shown that
40 % of MTCT are due to insufficient antenatal ART for the
women, even though half of them were diagnosed pre-
conception [69]. It appears that there remain missed opportu-
nities for prevention of MTCT which may be improved by
better engagement and retention in care and by providing
support for women before, during and after pregnancy, to
achieve and sustain viral suppression [69, 70].
Social Inequalities
The HIVepidemic inWestern Europe is concentrated inMSM
and PWID, but also disproportionately affects other
marginalised populations including migrants, sex workers,
transgender people and prisoners. HIV-related stigma and
discrimination are commonly faced by these populations,
acting as a major barrier to the integral care and support that
is needed. These barriers can hinder the success of interven-
tions and programmes to provide access to prevention
schemes, HIV testing, linkage to and retention in care, and
use of ART [35, 71–73]. We highlight the recent events in
Greece as a regretful example, where police detained, tested
and then publicised people’s HIV status [74]. These actions, as
a consequence of the change in law, have and will continue to
damage and undo all the benefits which have taken place so
far to combat the epidemic.
The Euro HIV index 2009 was a study conducted to assess
the quality of HIV policies and services and the social in-
equalities present in 29 European countries. The study authors
concluded that the countries rated as having the best HIV care
were Luxembourg, Malta, Switzerland, Finland and the Neth-
erlands [75]. These countries were the ones with the most
effective prevention programmes and good access to care,
especially for people who are part of marginalised popula-
tions. Societal inequalities existed in varying degrees among
the countries surveyed, but the notable areas requiring im-
provements were the stigma and discrimination faced by
vulnerable and marginalised populations and lack of universal
access to HIV testing, care and treatment.
Conclusions
Although in Western Europe the absolute number of people
affected by HIV is relatively small compared to other areas
such as sub-Saharan Africa and Eastern Europe, it is still a
significant public health issue. Fortunately, many countries
within this region are resource-rich and have been equipped
with solid infrastructures and good quality healthcare systems.
Consequently, Western Europe leads globally in terms of the
accessibility and standard of HIV care, but even within this
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region, large differences are seen, as found in the Euro HIV
Index 2009. One issue that the study highlighted was the lack
of good epidemiological data. Understanding the individual
country epidemics, by means of collecting good quality sur-
veillance data, is crucial to be able to provide the appropriate
services and programs that are needed in these settings [76•].
Estimation of the number of people living with HIV and the
size of the undiagnosed proportion would therefore be very
informative for people working in public health and policy
makers.
With no evidence of a decline in HIV incidence in Western
Europe, it will be important to plan for and provide the
appropriate HIV services for years to come. Amajor challenge
which is faced by many countries already is taking care of the
ageing population, including people newly diagnosed but also
those who have lived with HIV for decades and are now
reaching ages where the risk of comorbidities are much great-
er. Lastly, there is still a vital need to address the barriers
which exist that prevent universal access to HIV prevention
services, treatment and care.
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